Aprea Therapeutics, Inc. (APRE) Financials

APRE Assets vs Liabilities

DateAssetsLiabilities
2023-09-30 25.8 million 5.5 million
2023-06-30 28.7 million 5.3 million
2023-03-31 32.0 million 5.5 million
2022-12-31 30.2 million 4.5 million

APRE Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-09-30 -2.3 million 76031
2023-06-30 -3.2 million 269323
2023-03-31 -3.0 million 16244
2022-12-31 -4.0 million 57355

APRE Net Income

No data available :(

APRE Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-09-30 25.4 million - -
2023-06-30 27.7 million - -
2023-03-31 31.0 million - -
2022-12-31 28.8 million - -

APRE Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-09-30 3.7 million
2023-06-30 3.7 million
2023-03-31 3.3 million
2022-12-31 1.7 million

APRE Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-09-30 84079 2.1 million 1.7 million -
2023-06-30 - 2.2 million 1.7 million -
2023-03-31 - 1.3 million 3.4 million -
2022-12-31 - 531406 2.1 million -

APRE Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-09-30 319468 -
2023-06-30 249688 -
2023-03-31 - 410
2022-12-31 - -

APRE

Price: $5.20

52 week price:
2.78
8.85

Earnings Per Share: 12.31 USD

P/E Ratio: 0.42

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Volume: 118567

Market Capitalization: 23.2 million

Links: